GT Medical Technologies Announces the Presentation of Clinical Data on GammaTile® Therapy in the Treatment of Recurrent Glioblastomas at the 2022 American Association of Neurological Surgeons Scientific Meeting

GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.

GammaTile® Brachytherapy in the Treatment of Recurrent Glioblastomas

Neuro-Oncology Advances 2021 | Dominic J Gessler, Elizabeth C Neil, Rena Shah, Joseph Levine, James Shanks, Christopher Wilke, Margaret Reynolds, Shunqing Zhang, Can Özütemiz, Mehmet Gencturk, Mark Folkertsma, W Robert Bell, Liam Chen, Clara Ferreira, Kathryn Dusenbery, Clark C Chen. GammaTile® Brachytherapy in the Treatment of Recurrent Glioblastomas [published online December 27, 2021]. https://doi.org/10.1093/noajnl/vdab185

Resection and Surgically Targeted Radiation Therapy for Initial or Salvage Treatment of Aggressive Meningioma: Results From a Prospective Trial

Clinical Neurosurgery | Leland Rogers, MD; Peter Nakaji, MD; Emad Youssef, MD; Kris A. Smith, MD; Joseph Zabramski, MD; Theresa Thomas, MS; Christopher Dardis, MD; Dilini Pinnaduwage, PhD; David G. Brachman, MD; St Joseph’s Hospital, Phoenix, AZ; Barrow Neurological Institute, Phoenix, AZ; GT Medical Technologies, Tempe, AZ.